Skip to content
Screener

Amphastar Pharmaceuticals AMPH Q3 2026 earnings

Reported August 6, 2026 · After market close

Revenue$183.9MBeat by $4.0M
EPS$0.91Beat by $0.29
Revenue estimate$179.9M
EPS estimate$0.62
“Our second quarter results reflect the continued execution of our long-term strategy to build a more diversified and innovative biopharmaceutical company. While we continued to navigate pricing and competitive dynamics across portions of our portfolio, we successfully achieved key goals including overall revenue growth, expansion of gross margins, meaningful launches of new products, and continued advancement from both our generic and proprietary development pipelines. These results demonstrate the strength of our integrated business model and position us well for long-term sustainable growth.”
Dr. Jack Zhang

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$197.9M
EPS estimate$0.86

FAQ

When did Amphastar Pharmaceuticals report Q3 2026 earnings?
Amphastar Pharmaceuticals (AMPH) reported Q3 2026 earnings on August 6, 2026 after market close.
What were Amphastar Pharmaceuticals's Q3 2026 revenue and EPS?
Amphastar Pharmaceuticals reported revenue of $183.9M and eps of $0.91 for Q3 2026.
Did Amphastar Pharmaceuticals beat estimates in Q3 2026?
Revenue beat the consensus estimate of $179.9M by $4.0M. EPS beat the consensus estimate of $0.62 by $0.29.
How did Amphastar Pharmaceuticals's Q3 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 5.4% from $174.4M a year earlier and eps grew 7.1% from $0.85.
Where can I find Amphastar Pharmaceuticals's Q3 2026 SEC filings?
You can read the 8-K earnings release (0001297184-26-000045) and the 10-Q periodic report (0001297184-26-000047) directly on SEC EDGAR. The filing index links above go to sec.gov.